The Plasma Diafiltration Therapy of Hepatic Failure
Study of High - Flux Plasma Diafiltration Based on Plasma - Saved Mode in the Treatment of Patients With Hepatic Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: zhiyu zeng
- Phone Number: 008615880447131
- Email: 498289727@qq.com
Study Locations
-
-
Fujian
-
Fuzhou, Fujian, China, 350025
- Fuzhou General Hospital, Xiamen Univ
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- hepatic failure on Medium period
- Model for End-Stage Liver Disease (MELD) <30 and >20
- age > 18 years and <70years
- Written informed consent
Exclusion Criteria:
- Active bleeding or disseminated intravascular coagulation
- allergic to blood products or drugs such as plasma, heparin and protamine
- hemodynamic instability
- cardiovascular and cerebrovascular accidental infarction instability Period
- extravascular hemolysis
- severe sepsis
- Tumor on ultrasonography, CT or MRI examination
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: simple plasma exchange group
The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.
|
simple plasma exchange treatment
|
|
Active Comparator: conventional PDF treatment group
The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours.
the application plasma volume 1500 ml .
The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
|
conventional PDF treatment group
|
|
Active Comparator: less plasma PDF treatment group
The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h.
All patients are required to apply plasma 1000ml.
Use plasma substitutes: 300ml NS+200ml 5% albumin.
The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
|
less plasma Plasma diafiltration treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Model for end-stage liver disease (MELD score)
Time Frame: month 3
|
MRLD=R=3.8ln[TBIL(mg/dl)]+11.2ln(INR)+9.6ln
[Cr(mg/dl)]+6.4(etiology:Bile or alcoholic 0,others 1)。
|
month 3
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cytokine
Time Frame: Month 3
|
The concentration of cytokines(TNF-α、IL-6、IL-8、IL-10)will be tested
|
Month 3
|
|
blood platelet count
Time Frame: Month 3
|
To observe the changes in platelet count before and after the treatment
|
Month 3
|
|
the number of artificial liver treatment
Time Frame: Month3
|
Count the number of artificial liver treatments during hospitalization
|
Month3
|
|
the concentration of plasma ammonia
Time Frame: Month 3
|
To observe the changes of plasma ammonia before and after the treatment
|
Month 3
|
|
sequential organ failure assessment score(SOFA score)
Time Frame: Month 3
|
PaO₂(0:>53.33,1:39-53.33,2:26.66-40,3:13.33-26.67,4:≤13.33);Platelet
count(10/L)(0:>150,1:101-150,2:51-100,3:21-50,4:<21);Respiratory support(3:NO,4:yes);TBIL(0:<20,1:20-32,2:33-101,3:102-204,4:>204);Glasgow Coma Scale(0:15,1:13~14,2:10~12,3:6~9,4:<6);Cr(umol/L)(0:<110,1:110-170,2:171-299,3:300-440,4:>440);Level of hypotension (vasopressor status for ≥1 hr)(0:No hypotension;1:MAP <70,2:On vasopressors, dopamine <5 µg/kg/min OR dobutamine (any dose),3:Dopamine >5 µg/kg/min OR Epi/Norepi <0.1µg/kg/min;4:Dopamine >15 µg/kg/min OR Epi/Norepi >0.1 µg/kg/min)
|
Month 3
|
|
survival rate
Time Frame: Month 3
|
To count the survival rate after the treatment
|
Month 3
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2017L09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.